Vancomycin derivatives active against resistant bacterial nosocomial infections

万古霉素衍生物对耐药细菌医院感染具有活性

• 批准号: nhmrc : 631632
• 负责人: Prof David Paterson
• 金额: $ 50.73万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/vancomycin-derivatives-active-nosocomial-infections/98939
• 关键词: Vancomycin; derivatives; active; against; resistant

Bacterial infection is a leading cause of death worldwide and the emergence of superbugs that are resistant to multiple treatments is becoming a major global concern. Vancomycin is the drug of last resort for the treatment of hospital-acquired Gram -positive bacterial infections. We will synthetically modify vancomycin by incorporating naturally occurring membrane-associative peptides to produce novel antibiotics with multiple modes of action to avoid existing bacterial resistance mechanisms.

细菌感染是全球死亡的主要原因，对多种治疗具有耐药性的超级细菌的出现正在成为全球关注的主要问题。万古霉素是治疗医院获得性革兰氏阳性细菌感染的最后药物。我们将通过整合天然存在的膜结合肽来合成修饰万古霉素，以产生具有多种作用模式的新型抗生素，以避免现有的细菌耐药机制。